GlassScriptPhysician profile
Kevin Gregory Pollock
NPI 1942679196
$3,236.71
in general payments reported to CMS, 2019-2025
12 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $675 · 2023: $635 · 2024: $784 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,418.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,034.36 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Micra, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $979.96 | 2021-2025 | Assurity, Jot Dx, Aveir |
| Boston Scientific Corporation | $782.82 | 2021-2025 | Watchman Flx, Watchman Access System, General - Therapies |
| Pfizer INC. | $88.27 | 2022-2024 | |
| Biosense Webster, INC. | $81.26 | 2025 | Carto 3 |
| Atricure, INC. | $70.25 | 2022 | |
| Biotronik INC. | $60.22 | 2022-2025 | Rivacor 7 Dr-T, Amvia Edge, Acticor 7 Vr-T Dx |
| Janssen Pharmaceuticals, INC | $41.00 | 2023-2024 | Xarelto |
| Edwards Lifesciences Corporation | $35.18 | 2024 | Evoque |
| E.R. Squibb & Sons, L.L.C. | $24.63 | 2024 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $21.17 | 2023 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.59 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.